Comparisons of the receiver operating characteristic (ROC) curves for prediction of survival by the EZH2 score, TNM stage, and H3K27me3 score.

<p>(A) (E) DFS, (B) (F) OS in the training set. (C) (G) DFS, (D) (H) OS in the validation set. (A-D) the area under the ROC curves (AUROC) of EZH2 score versus the AUROC of TNM stage, or H3K27me3 score. (E-H) the AUROC of the combined EZH2 and TNM stage model versus the AUROC of the TNM stage or EZH2 expression alone model.</p

Kaplan-Meier analysis of disease-free survival (DFS) in renal cell carcinoma according to expression of the EZH2 or H3K27me3 score.

<p>(A), (D) all patients in the training set. (B), (E) patients with I+II stage disease in the training set. (C), (F) patients with III+IV stage disease in the training set. (G), (J) all patients in the validation set. (H), (K) patients with I+II stage disease in the validation set. (I), (L) patients with III+IV stage disease in the validation set. </p

The expression of EZH2 and H3K27me3 in human samples.

<p>Representative EZH2 and H3K27me3 immunohistochemical staining in renal cell carcinoma (200×magnification). (A-H) Positive EZH2 (black arrow) and H3K27me3 (white arrow) display a nuclear staining. (A) negative in RCC (E) negative in none tumor tissue (B-D) EZH2 positive (F-H) H3K27me3 positive (B) (F) staining intensity index-1socre (C) (G) staining intensity index-2 score (D) (H) staining intensity index-3 score (I) the expression of EZH2 and H3K27me3 was detected in all 10 cases of RCC tissues compared to adjacent non-RCC tissues. N, non-RCC tissue; T, RCC tissue.</p

Kaplan-Meier analysis of overall survival (OS) in renal cell carcinoma according to expression of the EZH2 or H3K27me3 score.

<p>(A), (D) all patients in the training set. (B), (E) patients with I+II stage disease in the training set. (C), (F) patients with III+IV stage disease in the training set. (G), (J) all patients in the validation set. (H), (K) patients with I+II stage disease in the validation set. (I), (L) patients with III+IV stage disease in the validation set. </p

Multivariate analyses of selected outcomes.

<p>Multivariate analyses of selected outcomes.</p

The supra-12th rib mini-flank approach for managing renal lesions.

<p>Renal clear cell carcinoma in the upper pole of the right side (A, D, G): The length of incision after MI-OPN (A); The length of the lesion after MI-OPN (D); Coronal reconstruction demonstrates a renal mass in the upper pole of the right kidney (G). Renal angiomyolipoma in the left side (B, E, H): The length of incision after MI-OPN (B); The length of the lesion after MI-OPN (E); Axial computed tomography (CT) scan shows a mass in the left kidney with low-density dark areas (H). Duplex kidney in the right side (C, F, I): C The length of incision after MI-OPN (C); The length of the lesion after MI-OPN (F); Coronal reconstruction demonstrates the right duplex kidney (I).</p

Surgical features stratified by group.

<p>OT = operative time; WIT = Warm ischemia time; LOS =  length of stay; EBL =  estimated blood loss.</p

Demographic and clinical characteristics of patients.

<p>VS  =  versus; MI-OPN =  mini-incision open partial nephrectomy; OPN =  open partial nephrectomy; LPN =  laparoscopic partial nephrectomy; BMI =  body mass index; eGFR  =  estimated glomerular filtration rate; SD =  standard deviation.</p